PubRank

Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer (PROFILER)

Clinical Trial ID NCT01774409

PubWeight™ 2.25‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01774409

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mutations of the BRAF gene in human cancer. Nature 2002 65.42
2 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
3 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 45.46
4 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 36.78
5 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 35.24
6 High frequency of mutations of the PIK3CA gene in human cancers. Science 2004 27.94
7 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 24.88
8 The cancer genome. Nature 2009 23.13
9 International network of cancer genome projects. Nature 2010 20.35
10 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 13.98
11 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005 13.40
12 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003 11.33
13 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 8.86
14 Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007 7.49
15 Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004 5.13
16 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006 4.92
17 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
18 Clinical implications of the cancer genome. J Clin Oncol 2010 3.11
19 Making sense of cancer genomic data. Genes Dev 2011 3.01
20 Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009 2.51
21 Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011 2.38
22 The genetic basis for cancer treatment decisions. Cell 2012 2.03
23 CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004 1.35
24 Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res 2009 1.35
25 Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012 1.26
26 Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011 1.23
27 Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001 1.21
28 Impact of genomics on personalized cancer medicine. Clin Cancer Res 2012 1.06
29 Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology 2012 1.05
30 BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011 0.90
31 General morphological and biological features of neoplasms: integration of molecular findings. Histopathology 2008 0.81
32 ESMO Clinical Practice Guidelines: development, implementation and dissemination. Ann Oncol 2010 0.80
33 The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget 2015 0.75
34 Equal access to innovative therapies and precision cancer care. Nat Rev Clin Oncol 2016 0.75
35 Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer 2016 0.75
Next 100